Effect of dexmedetomidine on perioperative hemodynamics and organ protection in children with congenital heart disease: A randomized controlled trial

Medicine (Baltimore). 2021 Jan 8;100(1):e23998. doi: 10.1097/MD.0000000000023998.

Abstract

Background: This study aimed to investigate the effects of dexmedetomidine (Dex) on hemodynamics and organ protection in congenital heart disease (CHD) children who underwent open-heart surgery under cryogenic cardiopulmonary bypass.

Methods: Ninety children were randomly allocated to group C (0.9% saline 0.2 μg/kg/hour), group D1 (Dex 0.2 μg/kg/hour), and group D2 (Dex 0.4 μg/kg/hour) (n = 30 per group). All participants received fentanyl, propofol and 1% sevoflurane for anesthesia induction. Hemodynamic data were measured from T0 (before the induction) to T7 (30 minutes after extubation). The difference of arterial internal jugular vein bulbar oxygen difference and cerebral oxygen extraction ratio were calculated according to Fick formula. Enzyme-linked immunosorbent assay was performed to detect the serum myocardial, brain and kidney injury markers. The incidence of acute kidney injury (AKI) was calculated by serum creatinine level. Tracheal extubation time, postoperative pain score and emergence agitation score were also recorded.

Results: Compared with group C, group D1, and D2 exhibited reduction in hemodynamic parameters, myocardial and brain injury indicators, and tracheal extubation time. There were no significant differences in blood urea nitrogen and neutrophil gelatinase-associated lipocalin or incidence of AKI among the 3 groups. Besides, the incidence of tachycardia, nausea, vomiting and moderate agitation, and the FLACC scale in group D1 and D2 were lower than those in group C. Moreover, Dex 0.4 g/kg/hour could further reduce the dosage of fentanyl and dopamine compared with Dex 0.2 g/kg/hour.

Conclusions: Dex anesthesia can effectively maintain hemodynamic stability and diminish organ injuries in CHD children.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravenous
  • Adrenergic alpha-2 Receptor Agonists / standards
  • Adrenergic alpha-2 Receptor Agonists / therapeutic use
  • Child
  • Child, Preschool
  • China
  • Dexmedetomidine / standards*
  • Dexmedetomidine / therapeutic use
  • Female
  • Heart Septal Defects / drug therapy*
  • Heart Septal Defects / physiopathology
  • Hemodynamics / drug effects
  • Hemodynamics / physiology
  • Humans
  • Hypnotics and Sedatives / standards
  • Hypnotics and Sedatives / therapeutic use
  • Male
  • Midazolam / therapeutic use
  • Perioperative Care
  • Treatment Outcome

Substances

  • Adrenergic alpha-2 Receptor Agonists
  • Hypnotics and Sedatives
  • Dexmedetomidine
  • Midazolam

Supplementary concepts

  • Atrioventricular Septal Defect